Clinical Trial

Very Early PET-response Adapted Targeted Therapy for Advanced Hodgkin Lymphoma: a Single -Arm Phase II Study

Study acronym: COBRA
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The main objective of this trial is to assess whether treatment adaptation based on a very early FDG-PET/CT results in improved efficacy while minimizing treatment toxicity in advanced stage Hodgkin Lymphoma (HL) patients treated with brentuximab vedotin (BV)-containing regimens.
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2018-04-24; most recent amendment 2025-08-04.
Status change: Recruiting → Active, Not Recruiting 2022-05-04
Status change: Not Yet Recruiting → Recruiting 2020-04-01
Trial Details
NCT Number NCT03517137
Lead Sponsor European Organisation for Research and Treatment of Cancer - EORTC
Conditions Advanced Hodgkin Lymphoma
Enrollment 150 participants
Start Date 2019-08-01
Primary Completion 2023-08-28 (estimated)
Study Completion 2026-11-16 (estimated)
Updated on ClinicalTrials.gov 2025-08-11